Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia

• Published in: Frontiers in immunology Vol. 12; p. 730970
• Main Authors: Bou-Tayeh, Berna, Laletin, Vladimir, Salem, Nassim, Just-Landi, Sylvaine, Fares, Joanna, Leblanc, Raphael, Balzano, Marielle, Kerdiles, Yann M, Bidaut, Ghislain, Hérault, Olivier, Olive, Daniel, Aurrand-Lions, Michel, Walzer, Thierry, Nunès, Jacques A, Fauriat, Cyril
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers 17.12.2021; Frontiers Media S.A
• Subjects: acute myeloid leukemia; Animals; Case-Control Studies; Cells, Cultured; chronic stimulation; Disease Models, Animal; exhaustion; Female; Humans; IL-15/mTOR signaling; Immunology; Interleukin-15 - metabolism; Interleukin-15 - pharmacology; Killer Cells, Natural - immunology; Leukemia, Myeloid, Acute - blood; Leukemia, Myeloid, Acute - immunology; Life Sciences; Male; metabolism; Mice; Mice, Inbred C57BL; Mice, Transgenic; natural killer cells; Signal Transduction - drug effects; Signal Transduction - genetics; TOR Serine-Threonine Kinases - metabolism; exhaustion; natural killer cells; IL-15/mTOR signaling; metabolism; acute myeloid leukemia; chronic stimulation
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.730970

Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation , suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML.